The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression

European Neuropsychopharmacology

Volumn 25, Issue 4, 2015, Pages 441-453

  Kautzky, Alexander ^a   Baldinger, Pia ^a   Souery, Daniel ^b,c   Montgomery, Stuart ^d   Mendlewicz, Julien ^e   Zohar, Joseph ^f   Serretti, Alessandro ^g   Lanzenberger, Rupert ^a   Kasper, Siegfried ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c Psy Pluriel Centre Europèen de Psychologie Medicale   (Belgium)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e FREE UNIVERSITY OF BRUSSELS   (Belgium)

^f SHEBA MEDICAL CENTER   (Israel)

^g UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Clinical factors in depression; Clustering; Genetics in depression; Random forests; Treatment outcome; Treatment resistant depression

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCINEURIN; CATECHOL METHYLTRANSFERASE; CMP-N-ACETYLNEURAMINATE-POLY-ALPHA-2,8-SIALOSYL SIALYLTRANSFERASE; COMT PROTEIN, HUMAN; PPP3CC PROTEIN, HUMAN; SEROTONIN 2A RECEPTOR; SIALYLTRANSFERASE;

ADULT; ALGORITHM; ARTICLE; COMPARATIVE STUDY; DSM-IV; FEMALE; GENOTYPE; HUMAN; MACHINE LEARNING; MAJOR CLINICAL STUDY; MALE; MELANCHOLIA; MIDDLE AGED; MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; PANIC; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; RANDOM FOREST; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; CLUSTER ANALYSIS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; GENETICS; PHARMACOGENETICS;

ALGORITHMS; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CALCINEURIN; CATECHOL O-METHYLTRANSFERASE; CLUSTER ANALYSIS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, SEROTONIN, 5-HT2A; SIALYLTRANSFERASES; TREATMENT OUTCOME;

EID: 84928203530     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.01.001     Document Type: Article

References (50)

1. Arias B., Fabbri C., Gressier F., Serretti A., Mitjans M., Gasto C., Catalan R., De Ronchi D., Fananas L. TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression. Neuropsychobiology 2013, 67:41-47.
2. Arias B., Gasto C., Catalan R., Gutierrez B., Pintor L., Fananas L. The 5-HT(2A) receptor gene 102T/C polymorphism is associated with suicidal behavior in depressed patients. Am. J. Med. Genet. 2001, 105:801-804.
3. Baldinger P., Hahn A., Mitterhauser M., Kranz G.S., Friedl M., Wadsak W., Kraus C., Ungersbock J., Hartmann A., Giegling I., Rujescu D., Kasper S., Lanzenberger R. Impact of COMT genotype on serotonin-1A receptor binding investigated with PET. Brain Struct. Funct. 2013.
4. Bath K.G., Lee F.S. Variant BDNF (Val66Met) impact on brain structure and function. Cogn., Affect. Behav. Neurosci. 2006, 6:79-85.
5. Bauer M., Pfennig A., Severus E., Whybrow P.C., Angst J., Möller H.J. World Federation of Societies of Biological Psychiatry Task Force on Unipolar Depressive Disorders, 2013. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J. Biol. Psychiatry 2013, 14(5):334-385.
6. Berlim M.T., Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can. J. Psychiatry Rev. Can. Psychiatr. 2007, 52:46-54.
7. Botta V., Louppe G., Geurts P., Wehenkel L. Exploiting SNP correlations within random forest for genome-wide association studies. PloS One 2014, 9:e93379.
8. Caldieraro M.A., Baeza F.L., Pinheiro D.O., Ribeiro M.R., Parker G., Fleck M.P. Prevalence of psychotic symptoms in those with melancholic and nonmelancholic depression. J. Nerv. Mental Dis. 2013, 201:855-859.
9. Chen C.C., Schwender H., Keith J., Nunkesser R., Mengersen K., Macrossan P. Methods for identifying SNP interactions: a review on variations of Logic Regression, Random Forest and Bayesian logistic regression. IEEE/ACM Trans. Comput. Biol. Bioinform./IEEE, ACM 2011, 8:1580-1591.
10. Chiesa A., Lia L., Alberti S., Lee S.J., Han C., Patkar A.A., Pae C.U., Serretti A. Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression. Int. J. Psychiatry Clin. Pract. 2014.
11. Crozatier C., Farley S., Mansuy I.M., Dumas S., Giros B., Tzavara E.T. Calcineurin (protein phosphatase 2B) is involved in the mechanisms of action of antidepressants. Neuroscience 2007, 144:1470-1476.
12. Fabbri C., Di Girolamo G., Serretti A. Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am. J. Med. Genet. Part B Neuropsychiatr. Genet.: Off. Publ. Int. Soc. Psychiatr. Genet. 2013, 162B:487-520.
13. Fabbri C., Marsano A., Albani D., Chierchia A., Calati R., Drago A., Crisafulli C., Calabro M., Kasper S., Lanzenberger R., Zohar J., Juven-Wetzler A., Souery D., Montgomery S., Mendlewicz J., Serretti A. PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. Pharmacogenomics J. 2014.
14. Fabbri C., Marsano A., Serretti A. Genetics of serotonin receptors and depression: state of the art. Current Drug Targets 2013, 14:531-548.
15. Garcia-Magarinos M., Lopez-de-Ullibarri I., Cao R., Salas A. Evaluating the ability of tree-based methods and logistic regression for the detection of SNP-SNP interaction. Ann. Hum. Genet. 2009, 73:360-369.
16. Gratten, J., Wray, N., Keller, M., Visscher, P., 2014. Large-scale genomics unveils the genetic architecture of psychiatric disorders. Nat. Neurosci. 17(6), 782-790.
17. Hamon M., Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2013, 45:54-63.
18. Heimann H. Therapy-resistant depressions: symptoms and syndromes. contributions to symptomatology and syndromes. Pharmakopsychiatr., Neuro-Psychopharmakol. 1974, 7:139-144.
19. Hildebrandt H., Muhlenhoff M., Weinhold B., Gerardy-Schahn R. Dissecting polysialic acid and NCAM functions in brain development. J. Neurochem. 2007, 103(Suppl. 1):S56-S64.
20. Hing B., Davidson S., Lear M., Breen G., Quinn J., McGuffin P., MacKenzie A. A polymorphism associated with depressive disorders differentially regulates brain derived neurotrophic factor promoter IV activity. Biol. Psychiatry 2012, 71:618-626.
21. Illi A., Setala-Soikkeli E., Viikki M., Poutanen O., Huhtala H., Mononen N., Lehtimaki T., Leinonen E., Kampman O. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 2009, 20:1125-1128.
22. Jiang C., Salton S.R. The role of neurotrophins in major depressive disorder. Transl. Neurosci. 2013, 4:46-58.
23. Jokela M., Keltikangas-Jarvinen L., Kivimaki M., Puttonen S., Elovainio M., Rontu R., Lehtimaki T. Serotonin receptor 2A gene and the influence of childhood maternal nurturance on adulthood depressive symptoms. Arch. Gen. Psychiatry 2007, 64:356-360.
24. Khait V.D., Huang Y.Y., Zalsman G., Oquendo M.A., Brent D.A., Harkavy-Friedman J.M., Mann J.J. Association of serotonin 5-HT2A receptor binding and the T102C polymorphism in depressed and healthy Caucasian subjects. Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 2005, 30:166-172.
25. Kocabas N.A., Antonijevic I., Faghel C., Forray C., Kasper S., Lecrubier Y., Linotte S., Massat I., Mendlewicz J., Noro M., Montgomery S., Oswald P., Snyder L., Zohar J., Souery D. Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder. Int. Clin. Psychopharmacol. 2011, 26:1-10.
26. Kocabas N.A., Faghel C., Barreto M., Kasper S., Linotte S., Mendlewicz J., Noro M., Oswald P., Souery D., Zohar J., Massat I. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study. Int. Clin. Psychopharmacol. 2010, 25:218-227.
27. Kraus C., Ganger S., Losak J., Hahn A., Savli M., Kranz G.S., Baldinger P., Windischberger C., Kasper S., Lanzenberger R. Gray matter and intrinsic network changes in the posterior cingulate cortex after selective serotonin reuptake inhibitor intake. NeuroImage 2014, 84:236-244.
28. Li P., Zhang P., Lin Y., Shan J., Wang J., Zhou T., Zhu Z., Huo K. PPP3CC feedback regulates IP3-Ca2+ pathway through preventing ITPKC degradation. Front. Biosci. 2013, 18:919-927.
29. Liaw A., Wiener M. Classification and regression by randomforest. R News 2002, 2(3):18-22.
30. Lin E., Chen P.S., Chang H.H., Gean P.W., Tsai H.C., Yang Y.K., Lu R.B. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2009, 33:1167-1172.
31. Maechler, M., Rousseeuw, P., Struyf, A., Hubert, M., Hornik, K., 2014. Cluster: cluster analysis basics and extensions. R package version 1.15.2.
32. Mallinckrodt C.H., Watkin J.G., Liu C., Wohlreich M.M., Raskin J. Duloxetine in the treatment of major depressive disorder: a comparison of efficacy in patients with and without melancholic features. BMC Psychiatry 2005, 5:1.
33. Mendlewicz J., Massat I., Linotte S., Kasper S., Konstantinidis A., Lecrubier Y., Montgomery S., Serretti A., Zohar J., Souery D. Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study. Int. Clin. Psychopharmacol. 2010, 25:297-301. Group for the Study of Resistant, D.
34. Nierenberg A.A., Katz J., Fava M. A critical overview of the pharmacologic management of treatment-resistant depression. Psychiatr. Clin. N. Am. 2007, 30:13-29.
35. Niitsu T., Fabbri C., Bentini F., Serretti A. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2013, 45:183-194.
36. Petit A.C., Quesseveur G., Gressier F., Colle R., David D.J., Gardier A.M., Ferreri F., Lepine J.P., Falissard B., Verstuyft C., Guiard B.P., Corruble E. Converging translational evidence for the involvement of the serotonin 2A receptor gene in major depressive disorder. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2014.
37. Porcelli S., Drago A., Fabbri C., Gibiino S., Calati R., Serretti A. Pharmacogenetics of antidepressant response. J. Psychiatry Neurosci.: JPN 2011, 36:87-113.
38. Rajewska-Rager A., Dmitrzak-Weglarz M., Kapelski P., Skibinska M., Kaczmarkiewicz-Fass M., Hauser J. [Association between polymorphisms of ins/del in the 5-HTT gene and T102C in the 5HTR2A gene and the drug response for escitalopram and nortriptyline in depressed patients]. Psychiatr. Pol. 2008, 42:903-914.
39. Sacchetti E., Scassellati C., Minelli A., Valsecchi P., Bonvicini C., Pasqualetti P., Galluzzo A., Pioli R., Gennarelli M. Schizophrenia susceptibility and NMDA-receptor mediated signalling: an association study involving 32 tagSNPs of DAO, DAOA, PPP3CC, and DTNBP1 genes. BMC Med. Genet. 2013, 14:33.
40. Schosser A., Calati R., Serretti A., Massat I., Kocabas N.A., Papageorgiou K., Linotte S., Mendlewicz J., Souery D., Zohar J., Juven-Wetzler A., Montgomery S., Kasper S. The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder-a European multicenter study. Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol. 2012, 22:259-266.
41. Schosser A., Serretti A., Souery D., Mendlewicz J., Zohar J., Montgomery S., Kasper S. European Group for the Study of Resistant Depression (GSRD)-where have we gone so far: review of clinical and genetic findings. Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol. 2012, 22:453-468.
42. Sen S., Duman R., Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry 2008, 64:527-532.
43. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):S22-S33. (Quiz 34-57).
44. Souery D., Amsterdam J., de Montigny C., Lecrubier Y., Montgomery S., Lipp O., Racagni G., Zohar J., Mendlewicz J. Treatment resistant depression: methodological overview and operational criteria. Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol. 1999, 9:83-91.
45. Souery D., Oswald P., Massat I., Bailer U., Bollen J., Demyttenaere K., Kasper S., Lecrubier Y., Montgomery S., Serretti A., Zohar J., Mendlewicz J. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J. Clin. Psychiatry 2007, 68:1062-1070. Group for the Study of Resistant, D.
46. Tansey K.E., Guipponi M., Hu X., Domenici E., Lewis G., Malafosse A., Wendland J.R., Lewis C.M., McGuffin P., Uher R. Contribution of common genetic variants to antidepressant response. Biol. Psychiatry 2013, 73:679-682.
47. Thase M.E., Rush A.J. When at first you don[U+05F3]t succeed: sequential strategies for antidepressant nonresponders. J. Clin. Psychiatry 1997, 58(Suppl. 13):S23-S29.
48. Whiteford H.A., Degenhardt L., Rehm J., Baxter A.J., Ferrari A.J., Erskine H.E., Charlson F.J., Norman R.E., Flaxman A.D., Johns N., Burstein R., Murray C.J., Vos T. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013, 382:1575-1586.
49. Yu J.J., Zhang Y., Wang Y., Wen Z.Y., Liu X.H., Qin J., Yang J.L. Inhibition of calcineurin in the prefrontal cortex induced depressive-like behavior through mTOR signaling pathway. Psychopharmacology 2013, 225:361-372.
50. Zhang J.P., Lencz T., Geisler S., DeRosse P., Bromet E.J., Malhotra A.K. Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia. Schizophr. Res. 2013, 146:285-288.